The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
High Dose Recombinant Human Growth Hormone (GH) Treatment of GH-Deficient Patients in Puberty Increases Near-Final Height: A Randomized, Multicenter Trial 1
Abstract
GH production rates markedly increase during human puberty, mostly as an amplitude-modulated phenomenon. However, GH-deficient children have been dosed on a standard per kg BW basis similar to prepubertal children. This randomized study was designed to compare the efficacy and safety of standard recombinant human GH (rhGH) therapy (group I, 0.3 mg/kg x week) vs. high dose therapy (group II, 0.7 mg/kg x week) in GH-deficient adolescents previously treated with rhGH for at least 6 months. Ninety-seven children with documented evidence of GH deficiency (peak GH in response to stimuli, <10 ng/mL), with either organic or idiopathic pathology, were recruited. Both groups were matched for sex (group I, 42 males and 7 females; group II, 41 males and 7 females), age [group I, 14.0+/-1.6 (+/-SD) yr; group II, 13.7+/-1.6], standardized height (group I, -1.4+/-1.1; group II, -1.2+/-1.1), bone age (group I, 13.1+/-1.3 yr; group II, 13.1+/-1.3) etiology, maximum stimulated GH, previous growth rate, and midparental target height. All subjects were in puberty (Tanner stage 2-5) at study entry. Of the 97 subjects enrolled, 45 were treated for 3 yr or more; 48 completed the study. Of the subjects who discontinued the study, the most common reason was satisfaction with their height, although others discontinued for adverse events or personal reasons. The frequency of patients who discontinued was the same in both groups. The primary efficacy analysis was the difference between dose groups for near-adult height, defined as the height attained at a bone age of 16 yr or more in males and 14 yr or more in girls; all subjects who qualified were included in the analysis. This difference was statistically significant at 4.6 cm by analysis of covariance (ANCOVA; P < 0.001; n = 75). For subjects who received at least 4 yr of rhGH treatment, the difference between dose groups at that time point was 5.7 cm (by ANCOVA, P = 0.024; n = 20). The mean height SD score at near-adult height was -0.7+/-0.9 in the standard dose group and 0.0+/-1.2 in the high dose group. At 36 months the cumulative change in height (centimeters) was 21.5+/-5.3 cm (group I) vs. 25.1+/-4.9 (group II; P < 0.001, by ANCOVA); the change in Bayley-Pinneau predicted adult height was 4.8+/-4.2 cm (group I) vs. 8.4+/-5.7 (group II; P = 0.032). Median plasma IGF-I concentrations at baseline were 427 microg/L (range, 204-649) in group I and 435 microg/L (range, 104-837) in group II; at 36 months they were 651 microg/L (range, 139-1079) in group I vs. 910 microg/L (range, 251-1843) in group II (P = NS). No difference in change in bone age was detected between groups at any interval. High dose rhGH was well tolerated, with a similar safety profile as standard dose treatment and no difference in hemoglobin A1c or glucose concentrations between groups. In summary, compared to conventional treatment, high dose rhGH therapy in adolescents 1) increased near-adult height and height SD scores significantly, 2) did not increase the rate of skeletal maturation, and 3) appears to be well tolerated and safe. In conclusion, high dose rhGH therapy may have a beneficial effect in adolescent GH-deficient patients, particularly those who are most growth retarded at the start of puberty.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Some studies have suggested that adult height may also be achieved by increasing the GH dose during puberty (to mimic the pubertal increase in GH secretion observed in individuals who are GH sufficient) or by delaying puberty using gonadotropin-releasing hormone analogs.103,104,106”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Giustina, A., & Veldhuis, J. D. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.6.0353 · Cited by 1,253
MAURAS, N., BLIZZARD, R. M., LINK, K., JOHNSON, M. L., ROGOL, A. D., & VELDHUIS, J. D. (1987) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-64-3-596 · Cited by 300
Self-citationRegulatory mechanisms of growth hormone secretion are sexually dimorphic.
Jaffe, C. A., Ocampo-Lim, B., Guo, W., Krueger, K., Sugahara, I., DeMott-Friberg, R., Bermann, M., & Barkan, A. L. (1998) · Journal of Clinical Investigation · doi:10.1172/jci2908 · Cited by 236
BOURGUIGNON, J.-P. (1988) · Endocrine Reviews · doi:10.1210/edrv-9-4-467 · Cited by 158
Metzger, D. L., & Kerrigan, J. R. (1994) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.79.2.8045971 · Cited by 152
Mauras, N., Rogol, A. D., & Veldhuis, J. D. (1990) · Pediatric Research · doi:10.1203/00006450-199012000-00018 · Cited by 127
Self-citation
Cited by
Grimberg, A., DiVall, S. A., Polychronakos, C., Allen, D. B., Cohen, L. E., Quintos, J. B., Rossi, W. C., Feudtner, C., Murad, M. H., & on behalf of the Drug and Therapeutics Committee and Ethics Committee of the Pediatric Endocrine Society (2016) · Hormone Research in Paediatrics · doi:10.1159/000452150 · Cited by 697
Growth Promotion Ethics and the Challenge to Resist Cosmetic Endocrinology
Allen, D. B. (2017) · Hormone Research in Paediatrics · doi:10.1159/000458526 · Cited by 554
Small for Gestational Age: Short Stature and Beyond
Saenger, P., Czernichow, P., Hughes, I., & Reiter, E. O. (2007) · Endocrine Reviews · doi:10.1210/er.2006-0039 · Cited by 528
Self-citationEndocrine Control of Body Composition in Infancy, Childhood, and Puberty
Veldhuis, J. D., Roemmich, J. N., Richmond, E. J., Rogol, A. D., Lovejoy, J. C., Sheffield-Moore, M., Mauras, N., & Bowers, C. Y. (2005) · Endocrine Reviews · doi:10.1210/er.2003-0038 · Cited by 452
Self-citationUse of Gonadotropin-Releasing Hormone Analogs in Children: Update by an International Consortium
Bangalore Krishna, K., Fuqua, J. S., Rogol, A. D., Klein, K. O., Popovic, J., Houk, C. P., Charmandari, E., & Lee, P. A. (2019) · Hormone Research in Paediatrics · doi:10.1159/000501336 · Cited by 293
Metadata
- Authors
- Mauras, N., Attie, K. M., Reiter, E. O., Saenger, P., & Baptista the Genentech Inc. Coopera, J.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2000-10
- Volume
- 85
- Issue
- 10
- Pages
- 3653-3660
- ISSN
- 0021-972X
- 1945-7197
- Cited by
- 12
- References
- 6
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.